RxDoctor Payments Data

Nicholas Howell, PA

Physician Assistant · Montgomery, ALNPI 1649570029

Payments from drug & device makers

$1,345in general payments, 2019–2025

Across 51 payments — averaging $26.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$192
  • Edwards Lifesciences$190
  • Novartis$180
  • AstraZeneca$169
  • Boehringer Ingelheim$132
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$125
  • plus $358 from 10 others

What the payments were for

  • Food & beverage$1,33299%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,345 in reported general payments places this provider in the 70th percentile of 846 physician assistant providers in Alabama.

See all physician assistant providers in Alabama

Medicare billing

Part B allowed, 2024
$48,840
Medicare patients
465
Services billed
960

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban185$180,020
EntrestoSacubitril/Valsartan62$79,413
MultaqDronedarone Hcl40$43,917
XareltoRivaroxaban32$23,473
BrilintaTicagrelor18$8,791
Metoprolol Succinate179$2,953
Diltiazem 24hr Er (Cd)Diltiazem Hcl66$2,720
Flecainide Acetate33$2,666
Atorvastatin Calcium129$2,213
Ranolazine ErRanolazine25$2,056
Carvedilol159$1,830
Amlodipine Besylate167$1,416
Losartan Potassium125$1,395
SotalolSotalol Hcl24$1,180
Rosuvastatin Calcium30$1,179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$58$180,020185 claims
NovartisEntresto$180$79,41362 claims
Sanofi-aventis U.S. LLCMultaq$23$43,91740 claims
Johnson & JohnsonXarelto$41$23,47332 claims
AstraZenecaBrilinta$169$8,79118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 846 physician assistant providers in Alabama.

Other physician assistant in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →